11/27/2022 0 Comments Cardinal chains level 83The simple payout ratio for the quarter was 55% compared to 45% for the fourth quarter of 2014. The Company also announces that its unaudited financial statements and management's discussion and analysis for the quarter ended March 31, 2015, will be available on the System for Electronic Document Analysis and Retrieval ("SEDAR") at and onĬardinal's website at First Quarter HighlightsĬardinal's total payout ratio for the first quarter of 2015 was 68% and it is expected the total payout ratio will be 82% for the year. (" Cardinal" or the " Company") ( CJ.TO) is pleased to announce its operating and financial results for the three months ended March 31, 2015. To read this article on click here.CALGARY, ALBERTA-(Marketwired - May 11, 2015) - Cardinal Energy Ltd. #CARDINAL CHAINS LEVEL 83 FREE#(XRAY) : Free Stock Analysis ReportĪVANOS MEDICAL, INC. (CAH) : Free Stock Analysis ReportĭENTSPLY SIRONA Inc. (DVA) : Free Stock Analysis ReportĬardinal Health, Inc. #CARDINAL CHAINS LEVEL 83 DOWNLOAD#Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. AVNS has an Earnings ESP of +15.72% and a Zacks Rank of 3. DVA has an Earnings ESP of +0.47% and a Zacks Rank of 3.Īvanos Medical, Inc. You can see the complete list of today’s Zacks #1 Rank stocks here.ĭaVita Inc. XRAY has an Earnings ESP of +6.77% and a Zacks Rank of 2. Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.ĭENTSPLY SIRONA Inc. Zacks Rank: The company carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. This is not the case here.Įarnings ESP: Cardinal Health has an Earnings ESP of -0.28%. Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. Here’s What the Quantitative Model Suggests However, stiff competition in each of the company’s business segments is likely to have weighed on the segment margins and consequently, might have limited profitability in the fiscal fourth quarter. The company’s fiscal fourth-quarter results are likely to reflect the impact of the same. Cardinal Health continues to show solid progress in both its segments and supply chain work streams, and generating near and long-term efficiencies. Per the fiscal second-quarter earnings call, the company has been boosting its core Medical and Pharmaceutical Distribution and product capabilities as it continues to adapt the resilient business models for the future. We anticipate these to get reflected in the fiscal fourth-quarter results. Price and EPS SurpriseĪpart from this, the company has been committed toward improving efficiencies across its Medical segment by refining commercial, operational and data capabilities. In the fiscal fourth quarter, revenues at this segment are likely to reflect increase in sales from personal protective equipment (PPE) and increase in volumes in its lab business. Notably, the segment manufactures products such as single-use surgical drapes, gowns and apparel, exam and surgical gloves, which may have driven sales in the to-be-reported quarter. Growth in sales from Pharmaceutical Distribution and Specialty Solutions customers is likely to have contributed to the aforementioned segment’s performance in the fiscal fourth quarter.Ĭardinal Health’s Medical unit may have contributed significantly to the overall fiscal fourth-quarter performance. In fact, higher contribution from key growth areas - Specialty and Connected Care - is likely to have favored the segment’s performance in the to-be-reported quarter. This might get reflected in the segment’s results in the to-be-reported quarter. Elective procedures and physician office visits are expected to recover to pre-COVID 19 levels exiting fiscal 2021, with a more substantial impact in the first half of the year. Factors to NoteĬardinal Health’s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States. The same for revenues stands at $39.94 billion, suggesting growth of 8.9% from the year-ago reported figure. Q4 Estimatesįor the fiscal fourth quarter, the Zacks Consensus Estimate for earnings is pegged at $1.18 per share, indicating a rise of 13.5% from the prior-year quarter. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 15.9%. In the last reported quarter, the company delivered a negative earnings surprise of 3.2%. CAH is scheduled to report fourth-quarter fiscal 2021 results on Aug 5, before the opening bell.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |